Literature DB >> 8109272

Comparison between radiosurgery and stereotactic fractionated radiation for the treatment of brain metastases.

A A De Salles1, M Hariz, C L Bajada, S Goetsch, T Bergenheim, M Selch, F E Holly, T Solberg, D P Becker.   

Abstract

This study evaluates the treatment of intracerebral brain metastases with single dose stereotactic radiosurgery in comparison to stereotactic fractionated radiotherapy (SFR). Twenty six patients with 41 lesions were evaluated. Thirty four lesions in 19 patients were treated with radiosurgery, and 7 lesions in 7 patients were treated with SFR. The radiosurgery group was treated with an average number of isocenters of 1.4, and an average of 9 arcs. The average dose was 2140 cGy delivered to the 70% isodose line. The average volume of the lesions was 5.22 cc. The SFR group lesions received a mean dose to the indicated area delivered by 4 to 6 coplanar fields. The dose was 600 cGy per fraction, 2 to 3 fractions were given. The average volume of the treated lesions was 21.2 cc. Follow-up extended from 2-18 months. Twenty five lesions of the radiosurgery group had image follow-up. The overall local control was seen in 92% of the patients. Six lesions of the SFR group had image follow-up, the local control was 83%. The small number in each group, the non-randomized nature of the study, and the relatively short follow-up preclude a definitive conclusion. SFR may be the method of choice for large lesions surrounded by significant edema. The delivery of the dose in large fractions may obviate the transient acute reactions seen when radiosurgical dose is delivered to large lesions surrounded by edema. However, both forms of therapy have proven to be effective in the control of brain metastases.

Entities:  

Mesh:

Year:  1993        PMID: 8109272     DOI: 10.1007/978-3-7091-9297-9_27

Source DB:  PubMed          Journal:  Acta Neurochir Suppl (Wien)


  7 in total

1.  Stereotactic radiosurgery and fractionated stereotactic radiotherapy: comparison of efficacy and toxicity in 260 patients with brain metastases.

Authors:  Emmanouil Fokas; Martin Henzel; Gunnar Surber; Gabriele Kleinert; Klaus Hamm; Rita Engenhart-Cabillic
Journal:  J Neurooncol       Date:  2012-04-15       Impact factor: 4.130

2.  Cyberknife hypofractionated stereotactic radiosurgery (HSRS) of resection cavity after excision of large cerebral metastasis: efficacy and safety of an 800 cGy × 3 daily fractions regimen.

Authors:  Che-Chuan Wang; Scott R Floyd; Chin-Hong Chang; Peter C Warnke; Chung-Ching Chio; Ekkehard M Kasper; Anand Mahadevan; Eric T Wong; Clark C Chen
Journal:  J Neurooncol       Date:  2011-08-31       Impact factor: 4.130

3.  Prospective study of stereotactic radiosurgery without whole brain radiotherapy in patients with four or less brain metastases: incidence of intracranial progression and salvage radiotherapy.

Authors:  Imjai Chitapanarux; Bryan Goss; Roy Vongtama; Leonardo Frighetto; Antonio De Salles; Michael Selch; Michael Duick; Timothy Solberg; Robert Wallace; Cynthia Cabatan-Awang; Judith Ford
Journal:  J Neurooncol       Date:  2003-01       Impact factor: 4.130

4.  Peritumoral edema after stereotactic radiosurgery for intracranial meningiomas and molecular factors that predict its development.

Authors:  Peter Kan; James K Liu; Merideth M Wendland; Dennis Shrieve; Randy L Jensen
Journal:  J Neurooncol       Date:  2007-01-24       Impact factor: 4.506

5.  Six degrees of freedom CBCT-based positioning for intracranial targets treated with frameless stereotactic radiosurgery.

Authors:  Anees Dhabaan; Eduard Schreibmann; Arsalan Siddiqi; Eric Elder; Tim Fox; Tomi Ogunleye; Natia Esiashvili; Walter Curran; Ian Crocker; Hui-Kuo Shu
Journal:  J Appl Clin Med Phys       Date:  2012-11-08       Impact factor: 2.102

Review 6.  Dose-Response Effect and Dose-Toxicity in Stereotactic Radiotherapy for Brain Metastases: A Review.

Authors:  Maxime Loo; Jean-Baptiste Clavier; Justine Attal Khalifa; Elisabeth Moyal; Jonathan Khalifa
Journal:  Cancers (Basel)       Date:  2021-12-02       Impact factor: 6.639

7.  Treatment of brain metastasis from lung cancer.

Authors:  Alexander Chi; Ritsuko Komaki
Journal:  Cancers (Basel)       Date:  2010-12-15       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.